Skip to main content
Hyper Corporation Inc. logo

Hyper Corporation Inc. — Investor Relations & Filings

Ticker · 065650 ISIN · KR7065650004 KO Telecommunications, computer programming, consultancy, computing infrastructure, and other information service activities
Open in API
Filings indexed 391 across all filing types
Latest filing 2020-05-15 Major Shareholding Noti…
Country KR South Korea
Listing KO 065650

About Hyper Corporation Inc.

https://hyper-corp.com/

Hyper Corporation Inc. is a company transitioning from a clinical-stage biopharmaceutical firm to a new-tech-based platform provider. Its core Bio & Healthcare division develops treatments and diagnostic technologies for neurodegenerative diseases like Alzheimer's, aiming to build a comprehensive digital senior healthcare platform. The company is expanding by integrating AI and blockchain technologies into new sectors. Its IP & Content division focuses on securing intellectual property and innovating content distribution, while its New Tech division develops platforms to connect online and offline services. This strategy fuses its biotechnology expertise with advanced IT to create new business models and services.

Recent filings

Filing Released Lang Actions
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a 'Report of Large Shareholding' (주식등의 대량보유상황보고서), which is a mandatory regulatory filing in South Korea under the Capital Markets Act. It details changes in share ownership by a major shareholder (Brain Contents Co., Ltd.) and its special related parties in the issuer (Medifron DBT). This type of filing is specifically designed to notify the market and regulators of significant changes in shareholding levels, which falls under the 'Major Shareholding Notification' category.
2020-05-15 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 95% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Korean Financial Supervisory Service (증권선물위원회) and Korea Exchange. This is a standard regulatory filing in South Korea used by insiders (directors, officers, and major shareholders) to disclose changes in their shareholdings. While it involves share ownership, it is specifically a regulatory disclosure of insider holdings rather than a general 'Director's Dealing' (DIRS) or 'Major Shareholding Notification' (MRQ) in the context of international reporting standards, but it fits the 'DIRS' category best as it reports the specific share ownership changes of a major shareholder/insider.
2020-05-15 Korean
분기보고서 (2020.03)
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Report' (분기보고서) for Medifron DBT Co., Ltd. covering the period from January 1, 2020, to March 31, 2020. It contains detailed company information, management discussion, capital changes, and financial data, which aligns with the definition of an Interim/Quarterly Report (IR). It is not a mere announcement or certification, as it provides substantive financial and operational disclosures. Q1 2020
2020-05-14 Korean
증권발행결과(자율공시)(국내사모CB 발행)
Capital/Financing Update Classification · 95% confidence The document is a 'Securities Issuance Result' (증권 발행결과) announcement regarding the issuance of convertible bonds (CB). It details the issuance amount, payment date, and confirms the completion of the financing activity. This falls under the category of capital and financing updates.
2020-05-12 Korean
증권발행결과(자율공시)(제3자배정 유상증자)
Share Issue/Capital Change Classification · 100% confidence The document is a regulatory filing from Medifron regarding the results of a third-party capital increase (issuance of new shares). It details the number of shares issued, the amount raised, and the payment date. This falls under the category of share issuance and capital changes.
2020-05-12 Korean
타법인주식및출자증권취득결정
Capital/Financing Update Classification · 98% confidence The document is a formal regulatory disclosure regarding the acquisition of shares in another company (New Mace Co., Ltd.) by Medifron. It details the acquisition amount, purpose, and financial status of the target company, which is a standard corporate filing for M&A or investment activity. Since it does not fit into specific categories like '10-K' or 'ER', and represents a specific corporate action regarding investment/acquisition, it is classified as a Regulatory Filing (RNS) as it serves as a general regulatory announcement for material corporate events.
2020-05-07 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.